Rheumnow Podcast

Pre-ACR25 (10.24.2025)

Dr. Jack Cush reviews the news and info reports the day before ACR 2025.

DERM on RheumNow (October 2025)

DERM on RheumNow PODCAST (October 2025)
Skin important Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. 
SHOW NOTES
1. Skin Biopsies to Predict Scleroderma Outcomes? 
2. Fibromyalgia in PsO & PsA is linked to greater treatment complexity and shorter biologic therapy survival. Retro matched 1:4 cohort study 61K PsO& 244K controls. FM prevalence 3.3% (OR 1.45). In PsA w/ FM, req more biologics w/ decr biologic survival (6 vs 10yrs) w/ incr switching (HR 1.82) https://buff.ly/TCc6Kc8
3. Guselkumab FDA Approved for Pediatric Psoriasis and Psoriatic Arthritis  https://rheumnow.com/news/guselkumab-fda-approved-pediatric-psoriasis-and-psoriatic-arthritis   
4. Sonelokimab (SLK) is a nanobody that inhibits IL-17 A&F. Phase 2 ARGO trial 207 active PsA pts Rx w/ SLK 120-mg or 60-mg q4wks or PBO or adalimumab. ACR50 at wk 12 was 60-mg WI=46%; 120-mg WI=46%; PBO 20%. PASI90: 60mg 77% vs 120mg 59% vs PBO 15% https://t.co/ra0NqvUEru https://t.co/FXT6kkXUzH  
5. Turkish study of 799 psoriasis pts - 30% had concurrent onset PsO & PsA & in 70% there was a long transition time (~13 yrs) from PsO-to-PsA. Factors assoc w/ prolonged interval included Depression, fatigue, scalp PsO(OR 7), nail PsO (3.2), +Fhx & enthesitis ever (OR 2) https://t.co/wqtSbeQ2vz
6. Mediterranean Diet Efficacy in Psoriasis  
7. Gender Complexities in Psoriatic Arthritis Treatment Outcomes

Bad Actor Cofactor (10.17.2025)

Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more.

Eating Crow (10.10.2025)

Associations in Rheumatology (10.3.2025)

Dr. Jack Cush reviews the news, journal reports and important associations in rheumatology from the past week on RheumNow.com.

ILD Diagnosis, Screening and Monitoring

Our final webinar in this month's Rheum to Breathe: ILD campaign brings together ILD experts to discuss best practices in diagnosis, screening, and monitoring, covering: tools, labs, and imaging; timing and frequency of screening; ILD screening in RA; and, referral strategies.

Panelists:
Shane Shapera, MD
Elana Bernstein, MD
Bryant England, MD
Moderator: Jack Cush, MD

A JAKi CHAT: Shared Decision-Making in RA Sponsored by AbbVie Medical Affairs + Health Impact

Experts Dr. Jeffrey Curtis and Dr. Kevin Winthrop discuss best practices for shared decision-making, how to talk with patients about the risks of poorly controlled RA, and ways to use a new tool for visualizing the long-term safety of a JAKi.

QD clinics on ILD - lessons from the Clinic #4

QD clinics on ILD - lessons from the Clinic; brought to during the "Rheum to Breathe" ILD campaign
ILD QD Clinic #4
ILD QD Clinics - Worsening Breathlessness in SSc ILD: The Pressure Is On 
ILD QD clinics on ILD #1 - Be Careful What you Look For 

Rheum + Pulm Collaborations in ILD

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 4: Rheum + Pulm Collaborations in ILD including The Rheumatologist and Pulmonologist: Different approaches to the same patient (Dr. Paul Dellaripa and Dr Rachel Putman).

ILD Assessment and Management

Rheum to Breathe Rx Update ILD Treatment and Guidelines Part 3: ILD Assessment and Management including: Biomarkers in ILD (Dr. Elena Joerns), How to Assess ILD in Patients (Dr. Janet Pope) and Management of SSc ILD (Dr. Alicia Hinze)